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has acceptable short-term survival, it is important to report longer
outcome durations and delayed complications. In this report, ret-
rospective analyses after transplantation from 2 centers from 1985
to 2003 were evaluated. Sixty-nine patients were evaluated, median
age 33 years (16–75), 43 men and 26 women, 55 had nodular
sclerosing HD, 7-lymphocyte predominant, 6-mixed cellular HD,
and 1-unknown subtype. Conditioning regimens consisted of TBI/
Cyclophosphamide in 11 patients, CBV in 38, BEAM/BEAC in 16,
and Busulfan/Cyclophosphamide in 4. Forty-nine patients received
peripheral stem cells (PSC), 17 received bone marrow (BM), and 3
received PSC plus BM. Seven patients (10%) had early mortality
(100 days) directly attributable to the transplant procedure. Four
were cardiac-related and two due to infection. Long-term non-
disease related mortality occurred in 16% secondary to MDS/
AML, cardiac, respiratory, and infectious-related causes. Thirty-
seven patients are alive, 30 patients have died, and 2 are lost to
follow-up. The OS at 5 years was 49% and 21% at 10-years,
respectively, while DFS at 5 years was 41% and 33% at 10 years,
respectively, indicating that patients were dying of other causes late
after transplantation. No difference in OS and DFS was noted
according to disease status at transplantation (CR vs active disease),
gender, or PSC vs BM. However, signiﬁcant differences were
noted in OS (P  .05) and DFS (P  .05) according to sensitivity
to salvage therapy administered prior to transplantation. Achieve-
ment of CR after transplantation had a signiﬁcant effect on OS. At
the median follow-up of 32 months, the OS is 83%, with a pre-
dicted OS at 10 years of 68%. Failure to achieve CR after trans-
plantation was associated with reduced OS, with 38% alive at 32
months, and all died by 10 years post-transplant. In conclusion,
autologous transplantation offers a good long-term survival option
for patients with relapsed/resistant HD. However, if CR is not
attained after transplantation, alternative therapies should be pur-
sued, because long-term outcomes for this patient group is dismal.
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AMIFOSTINE DOES NOT PROTECT AGAINST LIVER TOXICITY IN PA-
TIENTS RECEIVING DOSE-ESCALATED IV BUSULFAN (IVBU) AND STAN-
DARD DOSE CYCLOPHOSPHAMIDE IN AUTO BMT
Grosso, D.1, Brunner, J.1, Dessain, S.1, Ferber, A.1, Filicko, J.1,
Mookerjee, B.1, Shaw, L.2, Tedesco, N.1, Tran, H.3, Wagner, J.1,
Flomenberg, N.1 1. Thomas Jefferson University, Philadelphia, PA; 2.
University of Pennsylvania Medical Center, Philadelphia, PA; 3. M. D.
Anderson Cancer Center, Houston, TX.
Eight adult patients undergoing autologous transplant for hema-
tological malignancies were given a conditioning regimen of 4 daily
single doses of IVBU followed 24 hours later by 2 days of cyclo-
phosphamide (CP) at 60 mg/kg/day adjusted body weight. Ami-
fostine 740 mg/m2 was given just prior to each dose of IVBU and
CP in an attempt to ameliorate toxicities and allow for IVBU
dose-escalation. Dose-escalation of IVBU was based on AUC and
was done in phase I fashion. There were 4 planned cohorts, with a
targeted average daily AUC range for cohort 1 of 4400–5280
uMol-minute per day (midpoint 4800). This represents the AUC
range commonly achieved by single daily doses of 3.2mg/kg/day.
Each successive cohort of patients was to receive a dose of IVBU
that would result in an AUC that was 20% greater than the
previous group. Patients were given a test dose of 0.4 mg/kg of
IVBU over 15 minutes between 7 and 21 days prior to condition-
ing. Pharmacokinetics (PK) performed around the test dose were
used to base the ﬁrst 2 conditioning doses of IVBU. Additional
IVBU PK data was collected around conditioning doses 1and 3. If
the targeted AUC range was not achieved based on the IVBU PK
data for dose 1, IVBU doses were adjusted for days 3 and 4.
Acetaminophen and metronidazole were held during all IVBU
administration. Fungal prophylaxis was the same during IVBU test
and conditioning doses. Patients received phenytoin for seizure
prophylaxis. Five patients were enrolled in cohort 1. Three patients
achieved the desired AUC for this cohort. The other 2 exceeded
the target with AUCs that were within cohort 2 range. Despite
this, there was no VOD and only grade 0 to 1 mucositis or diarrhea
in this group. Three patients were enrolled in cohort 2 and met the
targeted average daily AUC range of 5281–6340 uMol-minute per
day (midpoint 5800) for that range. Two of 3 patients in cohort 2
developed late onset VOD (days 25, 22) and the protocol was
closed. One of these patients died from complications of VOD. In
cohort 2, there was 1 patient with grade 2 mucositis. Grade 0 to 1
mucositis and diarrhea was observed in the other patients. Amifos-
tine appears to ameliorate mucositis and diarrhea in patients re-
ceiving standard doses of IVBU and CP in autologous BMT but
does not protect against VOD in patients receiving dose-escalated
IVBU at least when combined with CP.
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DURATION OF ULCERATIVE MUCOSITIS AND OUTCOMES OF AUTOLO-
GOUS (AU) HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT)
FOLLOWING HIGH-DOSE MELPHALAN (MP) CONDITIONING FOR MUL-
TIPLE MYELOMA (MM)
Oster, G.1, Vera-Llonch, M.1, Ford, C.2, Lu, J.3, Khazanov, I.2,
Sonis, S.2 1. Policy Analysis, Inc (PAI), Brookline, MA; 2. Brigham and
Women’s Hospital, Boston, MA; 3. Amgen Inc, Thousand Oaks, CA.
Background: OM is a common toxicity of conditioning regi-
mens for HSCT that has been associated with adverse clinical and
economic outcomes. Methods: A retrospective study of approxi-
mately 400 consecutive HSCT recipients was undertaken at a
single academic center. Data were collected via chart review on
days with ulcerative mucositis and selected outcomes including
days with fever, days of parenteral narcotic therapy, incidence of
Grade III or IV (Common Toxicity Criteria) infection, total inpa-
tient days (LOS), and total inpatient charges. Data are reported
here for the 115 MM patients who underwent AU HSCT after
high-dose MP conditioning. Results: Mean age of study subjects
was 54 years. Seventeen percent of patients received total body
irradiation. Bone marrow was the source of most grafts. The
relationship between duration of ulcerative mucositis and the out-
comes of interest is reported below. Conclusions: Duration of
ulcerative OM is associated with worse clinical and economic
outcomes in MM patients undergoing AU HSCT following high-
dose MP conditioning (Table1).
Table 1. Outcomes of AU HSCT Following High-Dose Conditioning
for MM, by Days with Ulcerative Mucositis
Days with Ulcerative Mucositis (Quartile)
I II III IV
Outcomes n  32 n  33 n  25 n  25 P-value*
Fever days (mean,SD) 1.0 (1.9) 1.9 (3.2) 2.5 (2.5) 3.1 (3.7) .0058
Narcotic therapy days
(mean,SD) 0.7 (1.7) 3.9 (3.5) 4.4 (3.5) 8.8 (5.2) <.0001
Infection (%) 10.0 (31.3) 10.0 (30.3) 12.0 (48.0) 9.0 (36.0) .4115
LOS (mean,SD) 18.3 (3.1) 19.8 (3.5) 19.9 (3.4) 23.1 (3.5) <.0001
Inpatient charges
(mean,SD)
( 10,000) 11.7 (3.2) 12.3 (3.8) 11.8 (2.1) 15.5 (6.0) .0016
*Test for linear trend; Cochran-Armitage for dichotomous and
GLM for continuous measures.
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AUGMENTED HIGH DOSE CYCLOPHOSPHAMIDE, ETOPOSIDE, AND
CARMUSTINE FOLLOWED BY TRANSPLANTATION WITH PERIPHERAL
BLOOD STEM CELLS (PBSC) IN THE TREATMENT OF RELAPSED OR
REFRACTORY HODGKIN’S DISEASE
Schwartz, J.E.1, Robertson, M.J.1, Cornetta, K.G.1, Cripe, L.D.1,
Nelson, R.P.1, Yiannoutsos, C.T.1, Baute, J.A.1, Wood, L.L.1,
Abonour, R.1 Indiana University, Indianapolis, IN.
Introduction: The majority of patients with advanced stage
Hodgkin’s disease are cured with conventional dose combination
chemotherapy. However, patients with disease that fails to enter a
complete remission or that recurs after ﬁrst-line chemotherapy
have a poor prognosis. High dose chemotherapy with autologous
stem cell transplantation is a highly promising treatment. We
report the results of an augmented regimen containing cyclophos-
phamide, etoposide and carmustine followed by PBSC transplan-
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tation. Methods: Patients with relapsed or refractory Hodgkin’s
disease received cyclophosphamide 4.5 g/m2 for mobilization che-
motherapy, following which they were given G-CSF 10 g/kg/day
subcutaneously until stem cell collection. Patients then received
cyclophosphamide 1.8 g/m2 from day6 to day3, etoposide 800
mg/m2from day 6 to day 4, and carmustine 200 mg/m2 on day
6 and day 5. Beginning on Day 0, G-CSF 5 g/kg/day was
administered. Patients with bulky disease at relapse or multiple (2
or more) recurrences in the same nodal basin(s) after primary or
salvage therapies were eligible to receive consolidative radiother-
apy. Results: 40 patients were enrolled in this study. Thirty-nine
underwent autologous transplantation, with a median age of 31.8
years (range 17.5–74.4 years). Fifteen (37.5%) patients had primary
refractory disease. The median times to neutrophil and platelet
count recovery were 9 and 14.5 days, respectively. Twenty-two
(55%) patients relapsed with a median time to progression of 0.98
years (range 0.2–8.7 years). Overall survival was 50% with a me-
dian follow up of 5.4 years (range 2–8.7 years). Four patients died
of transplant related causes. These were: pulmonary ﬁbrosis, adult
respiratory distress syndrome, myocardial infarction prior to un-
dergoing transplantation, and cryptogenic organizing pneumonitis
(BOOP). Conclusions: Cyclophosphamide, etoposide, and car-
mustine is an effective high dose chemotherapy regimen for the
treatment of relapsed and refractory Hodgkin’s disease. However,
many of these patients unfortunately relapse. Novel approaches to
reduce the risk of relapse such as post transplant immunotherapy
or allogeneic transplantation should be investigated in this patient
population.
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HIGH DOSE MITOXANTRONE AND MELPHALAN FOLLOWED BY AUTOL-
OGOUS STEM CELL TRANSPLANTATION FOR LYMPHOID MALIGNAN-
CIES
Chan, G.W.1, Sprague, K.A.1, Klein, A.K.1, Klingemann, H.G.1 Tufts-
New England Medical Center, Boston, MA.
We evaluated outcomes in 44 patients with lymphoid malig-
nancies who underwent autologous stem cell transplantation
following a preparative regimen of mitoxantrone 20 mg/m2 over
1 hour  3 (total dose 60 mg/m2 ) and melphalan 60 mg/m2
over 1 hour  3 (total dose 180 mg/m2). Twelve patients (6
male) had nodular sclerosing (n  9) or mixed cellularity (n 
3) Hodgkin’s Lymphoma (HL), while 32 patients (17 male) had
diffuse large B-cell (n  21), T-lymphoblastic (n  4), mantle
cell (n  2), T cell rich B-cell (n  1), or anaplastic large cell
(n  3) non-Hodgkin’s lymphoma (NHL). The median age
among Hodgkin’s patients was 35 years (range 19–46 years)
while the median age among NHL patients was 47 years (range
23–63 years). Two patients were in ﬁrst complete remission
(CR), 1 patient in CR2, while 15 patients had partial response,
14 patients had relapsed disease, and 12 patients had refractory
disease at the time of transplant. All patients had a left ventric-
ular ejection fraction of at least 40% at the time of transplant.
Mitoxantrone and melphalan were well tolerated, with grade 3/4
mucositis the most common toxicity. Neutrophil engraftment
was seen at the median of 13 days (range 8–34 days). Day 100
transplant related mortality (TRM) was 3%. The 3-year disease
free (DFS) and overall survival (OS) were 63% and 67%, re-
spectively. Three-year DFS were similar between HL and NHL
patients (67% vs 63%: P  .66). There was no signiﬁcant
difference in 3-year DFS between patients with CR or PR versus
relapsed or refractory disease (66% vs 62%: P  .96). DFS were
similar among all disease subtypes. Congestive heart failure
occurred in on 3 patients (7%). One patient died of complica-
tions from CHF while 2 others recovered cardiac function. In
conclusion, mitoxantrone and melphalan preparative regimen is
well tolerated with minimal cardiac toxicity in patients with
lymphoid malignancies previously treated with anthracyclines.
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DIVIDED DOSE SCHEDULING OF MESNA TO PREVENT THE DEVELOP-
MENT OF CYCLOPHOSPHAMIDE-ASSOCIATED HEMORRHAGIC CYSTITIS
IN AUTOLOGOUS TRANSPLANT PATIENTS
Mc Pheeters, L.3, Kennedy, D.3, Holmberg, L.A.1,2 1. Fred Hutchinson
Cancer Research Center, Seattle, WA; 2. University of Washington
School of Medicine, Department of Medicine, Seattle, WA; 3. University
of Washington School of Medicine, Department of Pharmaceutical Sci-
ences, Seattle, WA.
Cyclophosphamide is an alkylating anti-neoplastic agent used for
mobilization and transplant regimens in ASCT patients. Hemor-
rhagic cystitis (HC) is a possible adverse reaction associated with
cyclophosphamide and may be prevented by the concomitant use
of mesna and intravenous (IV) hydration. Several mesna dosing
schedules have been studied in non-transplant clinical settings;
however, few studies have included ASCT patients. In order to
facilitate administration of cyclophosphamide in the outpatient
setting, and to reduce hospitalizations for continuous bladder irri-
gation, the standard of care at our institution since January 2003
has been to give mesna IV at the same dose of cyclophosphamide
in four equally divided doses at 15 minutes before, then 3, 6, and
8 hours after the administration of cyclophosphamide. A retrospec-
tive review was performed in ASCT patients to evaluate the effec-
tiveness of this mesna dosing schedule with aggressive IV hydra-
tion in preventing the development of HC. Cyclophosphamide
dosing in mobilization regimens was 3–4 gm/m2 and in transplant
regimens was 60–120 mg/kg. Of the 64 patients evaluated, 35
(55%) developed hematuria according to NCI Common Toxicity
Criteria, v. 3.0. Only one patient developed symptomatic HC.
Four patients developed hematuria with concurrent urinary tract
infections. There were no statistical differences between the
groups who did or did not develop HC in terms of age, gender,
underlying malignancy, past medical history, and concurrent use of
medications that place a patient at increased hemorrhagic risk.
More patients developed hematuria after receiving cyclophospha-
mide in transplant regimens than after mobilization regimens (24
vs 11 patients, P  .05). Patients who previously received cyclo-
phosphamide or ifosfamide as conventional chemotherapy were
more likely to develop hematuria (P  .025) after mobilization or
conditioning regimens. Patients were more likely to develop he-
maturia after the transplant regimen if they had a prior history of
receiving cyclophosphamide or ifosfamide (P  .001) with conven-
tional or mobilization chemotherapy. In conclusion, mesna IV
given in four equally divided doses with aggressive IV hydration is
effective in preventing the development of signiﬁcant HC. Addi-
tionally, this regimen facilitated the routine outpatient administra-
tion of high-dose cyclophosphamide.
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INTERLEUKIN 2 (IL-2) AND GRANULOCYTE-MACROPHAGE COLONY
STIMULATING FACTOR (SARGRAMOSTIN) (GM-CSF) FOLLOWING AU-
TOLOGOUS PERIPHERAL BLOOD STEM CELL TRANSPLANT (ASCT) FOR
BREAST CANCER
Holmberg, L.A.1,2,3, Bensinger, W.1,2,3 1. Fred Hutchinson Cancer
Research Center, Seattle, WA; 2. University of Washington, Depart-
ment of Medicine, Seattle, WA; 3. Puget Sound Oncology Consortium,
Seattle, WA.
Relapse remains a major problem after autologous stem cell
transplant for advanced breast cancer. GM-CSF has been shown in
vitro to enhance IL-2 mediated tumor lysis. We evaluated if the
addition of IL-2 and GM-CSF early after ASCT would reduce the
risk for relapse and prolong survival, Between April 1998 and April
2002, 50 patients with inﬂammatory stage IIIB (n  18) and
chemo-responsive stage IV (n  32) breast cancer were treated
with high dose Busulfan (12 mg/kg), melphalan (100 mg/m2), and
Thiotepa (500 mg/m2), followed by the infusion of autologous/
syngeneic peripheral blood stem ells (PBSC). Thirty to 100 days
after PBSC infusion after recovering from the acute toxicity of the
myeloablative therapy, patients were scheduled to receive 12 weeks
of IL-2 at 0.6  106 IU/m2 sc daily and GM-CSF 125 ug/m2 sc 3
times per week. All patients also took Tamoxifen 20 mg po qd
during the 12 weeks of immunotherapy. Twenty-six (52%) patients
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